Noble Financial restated their buy rating on shares of TherapeuticsMD (NASDAQ:TXMD) in a research report sent to investors on Monday, AnalystRatings.com reports. They currently have a $13.00 price target on the stock.
A number of other equities analysts have also weighed in on the stock. Oppenheimer cut their price objective on shares of TherapeuticsMD from $13.00 to $10.00 and set an outperform rating for the company in a research report on Tuesday, June 11th. BidaskClub raised shares of TherapeuticsMD from a strong sell rating to a sell rating in a research report on Saturday, August 10th. JPMorgan Chase & Co. cut their price objective on shares of TherapeuticsMD from $8.00 to $6.00 and set a buy rating for the company in a research report on Tuesday, June 11th. Cantor Fitzgerald reissued an overweight rating and issued a $13.00 price objective on shares of TherapeuticsMD in a research report on Wednesday, August 7th. Finally, Jefferies Financial Group cut their price objective on shares of TherapeuticsMD from $4.00 to $3.00 and set a hold rating for the company in a research report on Monday, July 15th. One analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. TherapeuticsMD currently has a consensus rating of Buy and a consensus target price of $9.28.
NASDAQ:TXMD opened at $2.97 on Monday. The firm has a 50 day simple moving average of $2.46 and a 200-day simple moving average of $3.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.39 and a quick ratio of 3.28. The firm has a market cap of $641.65 million, a PE ratio of -5.03 and a beta of 1.90. TherapeuticsMD has a 1-year low of $1.82 and a 1-year high of $6.94.
TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.01). The firm had revenue of $6.08 million during the quarter, compared to analyst estimates of $5.12 million. TherapeuticsMD had a negative net margin of 913.07% and a negative return on equity of 163.84%. The business’s quarterly revenue was up 60.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.15) EPS. As a group, sell-side analysts expect that TherapeuticsMD will post -0.73 earnings per share for the current fiscal year.
In related news, Director Angus C. Russell bought 35,000 shares of the stock in a transaction that occurred on Thursday, August 15th. The stock was purchased at an average cost of $2.83 per share, for a total transaction of $99,050.00. Following the completion of the acquisition, the director now owns 73,500 shares in the company, valued at $208,005. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider John C.K. Iv Milligan bought 15,000 shares of the stock in a transaction that occurred on Monday, August 12th. The stock was bought at an average price of $3.16 per share, with a total value of $47,400.00. Following the completion of the acquisition, the insider now owns 1,472,419 shares of the company’s stock, valued at approximately $4,652,844.04. The disclosure for this purchase can be found here. Over the last 90 days, insiders purchased 115,549 shares of company stock valued at $340,267. 18.91% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new stake in TherapeuticsMD in the first quarter valued at approximately $249,000. Amalgamated Bank grew its stake in TherapeuticsMD by 145.3% during the fourth quarter. Amalgamated Bank now owns 26,314 shares of the company’s stock worth $100,000 after buying an additional 15,586 shares during the period. Cetera Advisors LLC grew its stake in TherapeuticsMD by 13.8% during the first quarter. Cetera Advisors LLC now owns 77,725 shares of the company’s stock worth $380,000 after buying an additional 9,450 shares during the period. Private Ocean LLC purchased a new stake in TherapeuticsMD during the first quarter worth approximately $37,000. Finally, FMR LLC grew its stake in TherapeuticsMD by 0.5% during the first quarter. FMR LLC now owns 18,178,211 shares of the company’s stock worth $88,527,000 after buying an additional 89,870 shares during the period. Hedge funds and other institutional investors own 80.81% of the company’s stock.
TherapeuticsMD, Inc operates as a women's health care product company in the United States. The company's hormone therapy drug candidate is the TX-002HR, a natural progesterone formulation for the treatment of secondary amenorrhea without the potentially allergenic component of peanut oil. Its preclinical projects include the development of TX-005HR, a topical progesterone cream; TX-006HR, an estradiol and progesterone topical cream to penetrate human skin; and TX-00THR and TX-0008HR, which are transdermal patch forms.
Read More: What is a capital gains distribution?
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.